Previous close | 27.81 |
Open | 27.98 |
Bid | 0.00 x 2200 |
Ask | 0.00 x 36900 |
Day's range | 27.96 - 28.33 |
52-week range | 25.20 - 40.37 |
Volume | |
Avg. volume | 41,559,881 |
Market cap | 159.457B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (5.97%) |
Ex-dividend date | 09 May 2024 |
1y target est | N/A |
Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.